We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+13.81%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.53B
AUM Growth
+$567M
Cap. Flow
+$2.93M
Cap. Flow %
0.04%
Top 10 Hldgs %
36.11%
Holding
184
New
8
Increased
71
Reduced
51
Closed
13

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$20.9M
2
INCY icon
Incyte
INCY
+$16.3M
3
ISRG icon
Intuitive Surgical
ISRG
+$14.4M
4
DXCM icon
DexCom
DXCM
+$14.1M
5
CNC icon
Centene
CNC
+$13.5M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$40.9M
2
UNH icon
UnitedHealth
UNH
+$38.4M
3
ELV icon
Elevance Health
ELV
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TDOC icon
101
Teladoc Health
TDOC
$1.68B
$9.23M 0.12%
390,286
– –
BIIB icon
102
Biogen
BIIB
$30B
$7.87M 0.1%
28,404
-331
-1% -$93.5K
ONC
103
BeOne Medicines Ltd
ONC
$32.4B
$7.71M 0.1%
34,500
+27,500
+393% +$5.04M
NTRA icon
104
Natera
NTRA
$37.8B
$6.98M 0.09%
+173,812
New +$7.16M
RDY icon
105
Dr. Reddy's Laboratories
RDY
$10.5B
$6.43M 0.09%
627,500
+565,500
+912% +$6.1M
OLK
106
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$6.38M 0.08%
251,185
+20,663
+9% +$416K
BMRN icon
107
BioMarin Pharmaceuticals
BMRN
$11.5B
$6.28M 0.08%
60,685
+7,192
+13% +$675K
TFX icon
108
Teleflex
TFX
$5.94B
$6.26M 0.08%
25,066
-6,414
-20% -$1.42M
AUPH icon
109
Aurinia Pharmaceuticals
AUPH
$1.99B
$5.57M 0.07%
1,290,278
-1,556,179
-55% -$9.03M
AMWL icon
110
American Well
AMWL
$211M
$5.53M 0.07%
97,621
+9,136
+10% +$658K
AZN icon
111
AstraZeneca
AZN
$259B
$4.65M 0.06%
34,250
+12,050
+54% +$1.51M
JNJ icon
112
Johnson & Johnson
JNJ
$605B
$4.6M 0.06%
26,027
-4,644
-15% -$802K
LLY icon
113
Eli Lilly
LLY
$1.05T
$4.04M 0.05%
11,055
+1,565
+16% +$555K
SUPN icon
114
Supernus Pharmaceuticals
SUPN
$2.82B
$3.96M 0.05%
111,046
-8,232
-7% -$286K
MTEM
115
DELISTED
Molecular Templates, Inc.
MTEM
$3.7M 0.05%
751,867
– –
GH icon
116
Guardant Health
GH
$19.7B
$3.68M 0.05%
135,455
+73,372
+118% +$3.36M
BMY icon
117
Bristol-Myers Squibb
BMY
$124B
$3.62M 0.05%
50,255
+43,193
+612% +$3.26M
SGHT icon
118
Sight Sciences
SGHT
$276M
$3.6M 0.05%
294,606
– –
SGEN
119
DELISTED
Seagen Inc. Common Stock
SGEN
$2.91M 0.04%
22,626
-20,300
-47% -$2.62M
ZLAB icon
120
Zai Lab
ZLAB
$2.25B
$2.84M 0.04%
90,000
+53,400
+146% +$1.68M
ABBV icon
121
AbbVie
ABBV
$450B
$2.62M 0.03%
16,200
-797
-5% -$122K
CYTK icon
122
Cytokinetics
CYTK
$10.9B
$2.48M 0.03%
54,200
-17,000
-24% -$731K
AKRO
123
DELISTED
Akero Therapeutics
AKRO
$2.34M 0.03%
42,650
+1,016
+2% +$43.5K
BCYC
124
Bicycle Therapeutics
BCYC
$291M
$2.08M 0.03%
70,200
-27,900
-28% -$748K
QTTB icon
125
Q32 Bio
QTTB
$342M
$2.04M 0.03%
90,140
– –
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2022 Portfolio in Review

As of Q4 2022, Bellevue Group held 184 positions worth $7.53B, up 8.1% from $6.97B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group's Q4 2022 filing shows 8 new, 71 increased, 51 reduced and 13 closed positions. Its largest new stake was Natera: 173,812 shares worth $6.98M. The largest sale was Abiomed Inc, an estimated $40.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q4 2022 buy was Natera: 173,812 shares worth $6.98M.
  • Bellevue Group added most to Fate Therapeutics in Q4 2022, an estimated $20.9M increase.
  • Bellevue Group's biggest Q4 2022 reduction was UnitedHealth, cutting an estimated $38.4M.
  • Bellevue Group fully exited Abiomed Inc in Q4 2022, selling an estimated $40.9M.
  • Bellevue Group's ten largest holdings make up 36% of its $7.53B portfolio in Q4 2022.
  • Bellevue Group opened 8 new positions and closed 13 in Q4 2022.
  • Bellevue Group's portfolio value rose 8.1% quarter-over-quarter to $7.53B.

Based on Bellevue Group's 13F filing for Q4 2022, filed 14 Feb 2023.